The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lung Complications Closely Entwined with Rheumatologic Diseases

Lung Complications Closely Entwined with Rheumatologic Diseases

September 8, 2016 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Fischer recommended the pulmonologist’s “six-minute walk test” as a good way to assess functional status over time. It measures distance walked, heart rate, oxygen desaturation and how musculoskeletal disease affects performance, although it won’t distinguish ILD from pulmonary arterial hypertension (PAH) or other causes of hypoxia. He urged rheumatologists to keep their stethoscope handy and listen for crackles. But don’t assume that absence of crackles or of dyspnea means lack of ILD.

You Might Also Like
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
Explore This Issue
September 2016
Also By This Author
  • What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

A Paucity of Data for Effective Treatment of Scleroderma

Although scleroderma patients with ILD typically face poor prospects, Francesco Boin, MD, director of the Scleroderma Center at the University of California, San Francisco, offered some additional perspectives on their management, treatment and future directions for research. “Scleroderma is a heterogeneous, multi-organ disease with overlapping features and burden of side effects,” he said. There are no proven, targeted therapies—no disease-modifying anti-rheumatic drugs (DMARDs)—for scleroderma, and a paucity of evidence-based data exist for what is effective.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As a result, management strategies come to the fore—starting with encouragement for smoking cessation by the patient. Promotion of vaccinations is also important, because any infection in the lungs can trigger new disease. Other supportive care strategies include management of esophageal dysfunction, acid reflux and risk for aspiration; pneumocystis pneumonia prophylaxis when indicated; oxygen therapy to help minimize hypoxemia; patient education and support including referrals to peer groups; and palliative care for breathlessness, cough and depression.

“Educate the patients that this is a chronic disease for life,” Dr. Boin said. “Tell them that a group of professionals will be caring for them, but they also need to learn more about their disease.”
The challenge for rheumatologists is knowing who to treat and when to treat and distinguishing early vs. end-stage disease, he said. Not all patients are affected to the same degree, so it’s important to determine severity of disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“With a lot of these patients, where the course of their disease is relatively benign, we wonder: do we really need to treat?” Patients with the best chance of responding to treatment may be those with higher risk of declining lung function, predicted poor outcome or more extensive disease at presentation.

Dr. Boin also emphasized looking for changes in function and using pulmonary function tests to assess disease progression over time.

The efficacy of corticosteroids for CTD‑ILDs remains controversial because no randomized controlled trials have yet proved their efficacy at moderate to high doses. In scleroderma patients, there is also the potential risk of renal crisis and other side effects from corticosteroid treatment.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: California Rheumatology Alliance 2016, lung, patient care, Research, Rheumatic Disease, rheumatologist, TreatmentIssue: September 2016

You Might Also Like:
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.